Oncolytic adenovirus

From WikiMD's Wellness Encyclopedia

Oncolytic adenovirus is a type of virus that has been genetically modified to kill cancer cells. This is achieved by the virus selectively replicating in and killing cancer cells, while leaving normal cells unharmed. The use of oncolytic adenoviruses is a promising new approach in the treatment of cancer, and is currently being investigated in clinical trials.

History[edit | edit source]

The concept of using viruses to treat cancer, known as oncolytic virotherapy, has been around for over a century. However, it was not until the late 20th century that scientists began to genetically modify viruses to specifically target cancer cells. The first oncolytic adenovirus, ONYX-015, was developed in the 1990s and showed promising results in early clinical trials.

Mechanism of Action[edit | edit source]

Oncolytic adenoviruses work by exploiting the differences between normal and cancer cells. Cancer cells often have defects in their immune system response, which allows the virus to infect and replicate within these cells. The virus then causes the cancer cell to burst, releasing new virus particles that can infect other cancer cells. This process is known as lysis.

Clinical Trials[edit | edit source]

Several oncolytic adenoviruses are currently being tested in clinical trials for a variety of cancers. These include pancreatic cancer, lung cancer, breast cancer, and glioblastoma, among others. Early results have been promising, with some patients showing significant reductions in tumor size and improved survival rates.

Safety and Side Effects[edit | edit source]

Like all cancer treatments, oncolytic adenoviruses can cause side effects. These can include flu-like symptoms, such as fever and fatigue, as well as more serious complications like organ damage. However, because the viruses specifically target cancer cells, they are generally considered to be safer than traditional chemotherapy or radiation therapy.

Future Directions[edit | edit source]

Research into oncolytic adenoviruses is ongoing, with scientists continually working to improve the safety and effectiveness of these treatments. Future directions may include combining oncolytic adenoviruses with other cancer treatments, such as immunotherapy, to enhance their anti-cancer effects.

Oncolytic adenovirus Resources

Contributors: Prab R. Tumpati, MD